Seeking Alpha

Merck KGaA's (MKGAF.PK) Erbitux treatment helped patients with metastatic colon cancer live...

Merck KGaA's (MKGAF.PK) Erbitux treatment helped patients with metastatic colon cancer live around four months longer than Roche's Avastin in a head-to-head study. However, the overall response rate, as measured by tumor shrinkage, was the about same, as was the amount of time it took for the disease to worsen. A larger trial of the drugs is due to take place next year. Merck's U.S. partners in Erbitux are Eli Lilly (LLY) and Bristol-Myers Squibb (BMY). The findings were presented at the annual meeting of American Society of Clinical Oncology.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector